GSK, Pfizer and RSV
RSV vaccines from Pfizer, GSK take another hit with new FDA warning mandate
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare neurological condition that can cause paralysis.
GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome Warnings
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments to the vaccines’ labels.
Covid, flu and RSV rising in US
Hosted on MSN11h
FDA Adds Guillain-Barre Syndrome Warning to Two RSV VaccinesBefore the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...
Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.
“As of December 28, Oneida County has had 386 flu cases reported since the flu season began,” said Daniel W. Gilmore, Ph.D., ...
Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according ...
The CDC’s overall snapshot of respiratory illness activity in Florida remains very high. The CDC has measured moderate levels ...
For RSV in particular, nearly two dozen states are currently reporting high levels, according to the U.S. Centers for Disease ...
The Centers for Disease Control and Prevention measures viral activity levels in wastewater for many illnesses. Included ...
For most people RSV is like a cold, but for infants and older people it can lead to serious infections. Here's what to know.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback